# A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America

> **NCT03470103** · — · COMPLETED · sponsor: **Bayer** · enrollment: 643 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT03470103
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2020-09-21
- **Final completion:** 2021-01-15
- **Target enrollment:** 643 (ACTUAL)
- **Last updated:** 2021-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03470103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03470103, "A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03470103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*